JustGoLong
9 years ago
BIOYF - BioSyent Releases First Six Months 2015 Results-Six Month Sales Up 25%; Pharma Sales Up 25%; EBITDA Up 31%; Net Income Up 30%; Return on Equity 40%
TORONTO, ONTARIO -- (Marketwired) -- 08/12/15 -- BioSyent Inc.(BIOYF) ("BioSyent") released today a summary of its Second Quarter (Q2 2015) and first half financial results for the three and six months ending June 30, 2015. Key highlights include:
First six months (H1 2015) Sales of $6,900,098 increased by 25% versus H1 2014
H1 2015 Pharma sales of $6,565,300 increased by 25% versus H1 2014
First six months (H1 2015) Revenue has grown at a compound annual growth rate (CAGR) of 44% over the corresponding previous two years
H1 2015 EBITDA1 of $2,490,429 increased by 31% over H1 2014
H1 2015 Net Income After Tax of $1,813,751 increased by 30% over H1 2014
H1 2015 Fully Diluted EPS of $0.13 grew by 30% over H1 2014
Trailing Twelve Month (TTM) fully diluted EPS of $0.25 was 39% higher than $0.18 in the TTM period ending June 30, 2014
H1 2015 Return on Equity was 40% annualized
In Canada, FeraMAX® 150 share of doses increased by more than 18% in the January - May 2015 period versus a year ago ( Source data : IMS Health™ )
A large international FeraMAX® order representing sales of $627,512 received in the first quarter was postponed to Q3 2015 due to a delay in obtaining necessary importation clearances. Had this order been shipped in H1 2015, H1 2015 sales would have grown by 36% versus H1 2014. This order was shipped in the first week of August 2015
The Company remains debt-free and has an unutilized operating line of credit with Royal Bank of Canada of $1.55MM
Working capital, which is the difference between current assets and current liabilities, increased by 24% from $7,786,460 as at December 31, 2014 to $9,641,260 as at June 30, 2015.
Total Shareholder's Equity increased by 24% from $8,160,092 at December 31, 2014 to $10,087,481 at June 30, 2015.
An international FeraMAX® order of $627,512 received in Q1 2015, originally planned for Q2 2015 shipping, was postponed to Q3 2015 due to delay in obtaining necessary importation clearances. If this order had shipped as originally requested by the customer, H1 2015 sales would have grown by 36% versus H1 2014 and Q2 2015 pharma sales would have been +37% versus Q2 2014. This order has been shipped as of the date of this press release and will have a correspondingly positive effect on Q3 2015 results.
"For the first time, in June and July 2015, the Company's sales exceeded $1.5 million per month for two consective months," commented René Goehrum, President and CEO of BioSyent(BIOYF). "In Canada, in the second quarter both FeraMAX 150® and RepaGyn® had their second consective quarter of record shipments. This was backed up with strong year over year growth for Cathejell™ and FeraMAX Powder®. Additionally with the shipment of our largest FeraMAX® order ever to an overseas customer -- the international pharma business is on track to more than double this year."
The CEO presentation on the Second Quarter of 2015 is available at the following link www.biosyent.com/q2-15/
The Company's Consolidated Financial Statements and Management's Discussion & Analysis will be posted on www.sedar.com on August 12, 2015.
For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.
HallaDurg
10 years ago
BioSyent Releases Q2 and Six Month Results-Q2 Sales Increase 72%, Net Income After Tax Up 112%
https://docs.google.com/viewer?a=v&pid=sites&srcid=ZGVmYXVsdGRvbWFpbnxiaW9zeWVudHxneDo5ZGI3YmEwZDM4N2U4NzA
TORONTO, ONTARIO, Aug 21, 2014 (Marketwired via COMTEX) -- BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a summary of its Second Quarter (Q2 2014) and first half (H1 2014) financial results for the three and six months ending June 30, 2014. Key highlights include:
-- Q2 2014 Sales of $3,072,395 increased by 72% versus Q2 2013
-- First six months (H1 2014) Sales of $5,520,496 increased by 66% versus
H1 2013
-- Q2 2014 Revenue has grown at a compound annual growth rate (CAGR) of 68%
over the corresponding quarters of the last three years
-- First six months (H1 2014) Revenue has grown at a compound annual growth
rate (CAGR) of 70% over the corresponding 3 years period
-- Q2 2014 Pharmaceutical Sales of $2,893,162 were up 72% versus Q2 2013
-- H1 2014 Pharmaceutical Sales of $5,236,170 increased by 75% versus H1
2013
-- Nineteen consecutive quarters of continued pharmaceutical sales growth
-- Q2 2014 Net Income Before Tax of $1,219,855 increased by 125% versus Q2
2013
-- H1 2014 Net Income Before Tax of $1,907,527 increased by 86% versus
$1,024,927 in H1 2013
-- Q2 2014 Net Income After Tax of $888,805 increased by 112% versus Q2
2013
-- H1 2014 Net Income After Tax of $1,400,226 increased by 84% versus H1
2013
-- Q2 2014 Diluted EPS of $0.06 versus $0.03 in Q2 2013
-- Trailing twelve months (TTM) fully diluted EPS of $0.18
-- The company remains debt-free and has an unutilized operating line of
credit with Royal Bank of Canada
-- New Urgent Care product received Health Canada marketing approval in Q2
2014
-- Launched new Women's Health Product - RepaGyn(R) in Q2 2014
-- Pre-launch activity for a new Gastrointestinal Health product - launch
planned for fourth quarter of 2014
-- In July BioSyent in-licensed a third new Urgent Care Drug Product from
the same European partner
-- Selected as a TSX Venture 50 Top Performer for three consecutive years -
2012, 2013 and 2014
-- For the second consecutive year BioSyent named as one of Canada's
fastest growing companies in the Profit 500 rankings with a five year
growth rate of 608%
Total sales for Q2 2014 of $3,072,395, were 72% higher compared to $1,786,684 in the corresponding prior year period. Total Sales for H1 2014 of $5,520,496 were 66% higher than H1 2013.
Pharmaceutical Sales in Q2 2014 increased by 72% from $1,683,793 in Q2 2013 to $2,893,162 in Q2 2014. Total Pharmaceutical Sales for H1 2014 of $5,236,170 were 75% higher than H1 2013.
Net Income Before Tax for Q2 2014 was $1,219,855, which was 125% higher than $542,964 in Q2 2013. Net Income Before Tax for H1 2014 was $1,907,527 or 86% higher than the corresponding prior year period.
Net Income After Tax increased by 112% from $418,325 in Q2 2013 to $888,805 in Q2 2014. Net Income After Tax for H1 2014 was $1,400,226 or 84% higher than the corresponding prior year period.
Basic & Dilluted Earnings Per Share (EPS) was $0.06 in Q2 2014 vs. $0.03 in Q2 2013. H1 2014 Basic EPS was $0.10 vs. $0.06 in H1 2013. Diluted EPS in H1 2014 was $0.10 vs. $0.05 in H1 2013.
Working capital, which is the difference between current assets and current liabilities, increased by 34% from $4,405,910 as at December 31, 2013 to $5,890,238 as at June 30, 2014. Total Cash included in working capital on June 30, 2014 is $4,830,796. Total Shareholder's Equity increased by 31% from $4,854,630 at December 31, 2013 to $6,337,976 at June 30, 2014.
The Company plans to launch a new Gastrointestinal product in the fourth quarter of 2014. The Company also received Health Canada approval on one of its two urgent care products and is planning to launch the product in late 2014 or early 2015.
On July 23, 2014 BioSyent Pharma in-licensed a third urgent care product from an existing European partner. This product will be launched after Health Canada approval.
The Company's Consolidated Financial Statements and Management's Discussion & Analysis will be posted on www.sedar.com on August 21, 2014.
For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.
BioSyent will also release a CEO presentation on the Second Quarter at the following link www.biosyent.com/q2-14/.
About BioSyent Inc.
Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.
Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.
At the date of this press release the Company had 13,801,195 shares issued and outstanding.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Ask ADVFN Intelligence (AI)
stocktrademan
10 years ago
Hot Features
Premium
